S I Younkin

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Neurochemical research in dementia needs to move beyond descriptive inventories of neurotransmitter systems affected in the specific disorders and to link to molecular studies of mechanism and clinical studies of cognition. New advances in Alzheimer's Disease (AD), Huntington's Disease (HD), and Parkinson's Disease (PD) are being guided by models of how(More)
At present, the treatment options for Alzheimer’s disease are largely symptomatic giving rise to temporary remissions in cognitive decline or the amelioration of troublesome behavioural and psychological symptoms. However, as more is becoming known about the molecular biology of Alzheimer’s disease, there is a clear movement to treatments directed towards(More)
  • 1